Neurocrine Biosciences Inc. (NBIX) reported fourth-quarter 2025 results, delivering revenue of $805.5 million and showing strong year-over-year growth across profitability metrics.
Liquidity and balance-sheet highlights:
Compared with Street expectations and market reaction:
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Neurocrine Biosciences Inc. Insider Trading Activity
Neurocrine Biosciences Inc. insiders have traded $NBIX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KYLE GANO (Chief Executive Officer) has made 0 purchases and 3 sales selling 36,700 shares for an estimated $4,873,049.
- WILLIAM H RASTETTER sold 18,000 shares for an estimated $2,732,689
- GARY A LYONS sold 15,000 shares for an estimated $2,289,082
- GEORGE J MORROW sold 15,000 shares for an estimated $2,150,512
- LESLIE V NORWALK has made 0 purchases and 2 sales selling 6,190 shares for an estimated $945,701.
- ERIC BENEVICH (Chief Commercial Officer) sold 5,970 shares for an estimated $905,880
- DARIN LIPPOLDT (Chief Legal Officer) sold 4,376 shares for an estimated $698,615
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Neurocrine Biosciences Inc. Hedge Fund Activity
We have seen 383 institutional investors add shares of Neurocrine Biosciences Inc. stock to their portfolio, and 280 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 1,263,633 shares (+83.7%) to their portfolio in Q3 2025, for an estimated $177,388,800
- CITADEL ADVISORS LLC removed 1,255,836 shares (-61.3%) from their portfolio in Q3 2025, for an estimated $176,294,257
- UBS GROUP AG added 618,956 shares (+169.8%) to their portfolio in Q4 2025, for an estimated $87,786,529
- JENNISON ASSOCIATES LLC removed 519,953 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $73,744,933
- THRIVENT FINANCIAL FOR LUTHERANS removed 481,467 shares (-84.2%) from their portfolio in Q4 2025, for an estimated $68,286,464
- JPMORGAN CHASE & CO added 470,204 shares (+9.9%) to their portfolio in Q4 2025, for an estimated $66,689,033
- TWO SIGMA INVESTMENTS, LP added 347,565 shares (+inf%) to their portfolio in Q3 2025, for an estimated $48,791,174
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Neurocrine Biosciences Inc. Analyst Ratings
Wall Street analysts have issued reports on $NBIX in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 01/08/2026
- HC Wainwright & Co. issued a "Buy" rating on 12/17/2025
- Stifel issued a "Buy" rating on 12/11/2025
- TD Cowen issued a "Buy" rating on 12/05/2025
- Needham issued a "Buy" rating on 10/29/2025
- Piper Sandler issued a "Overweight" rating on 10/29/2025
- RBC Capital issued a "Outperform" rating on 10/29/2025
To track analyst ratings and price targets for Neurocrine Biosciences Inc., check out Quiver Quantitative's $NBIX forecast page.
Neurocrine Biosciences Inc. Price Targets
Multiple analysts have issued price targets for $NBIX recently. We have seen 13 analysts offer price targets for $NBIX in the last 6 months, with a median target of $179.0.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $178.0 on 01/23/2026
- Anupam Rama from JP Morgan set a target price of $177.0 on 01/12/2026
- Jeffrey Hung from Morgan Stanley set a target price of $175.0 on 01/08/2026
- Danielle Brill from Truist Securities set a target price of $169.0 on 01/08/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $198.0 on 12/17/2025
- Uy Ear from Mizuho set a target price of $175.0 on 12/12/2025
- Paul Matteis from Stifel set a target price of $188.0 on 12/11/2025
